The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
Background: Adjuvant platinum-based chemotherapy is standard of care for patients with resected stage IIA/B or IIIA NSCLC. Overall survival is suboptimal due to the high metastatic potential of early-stage NSCLC and there is substantial clinical need for additional efficacious adjuvant treatment opt...
Guardado en:
Autores principales: | Barbara Melosky, Parneet Cheema, Rosalyn A. Juergens, Natasha B. Leighl, Geoffrey Liu, Paul Wheatley-Price, Adrian Sacher, Stephanie Snow, Ming-Sound Tsao, Deanna McLeod, Quincy Chu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
SAGE Publishing
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b7c460474e584b6ca7677d4ff0d6ecf3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
False Dawn
por: Mohamed Aslam Haneef
Publicado: (1998) -
Economic classifications at the dawn of the new millennium
Publicado: (2017) -
Prediction of early recurrence and response to adjuvant Sorafenib for hepatocellular carcinoma after resection
por: Liming Zheng, et al.
Publicado: (2021) -
Red Dawn – the final episode of the Cold war
por: Ivan Kovačević, et al.
Publicado: (2016) -
PATHOLOGICAL ASSESSMENTOF TUMOR RESPONSE IN A NEO-ADJUVANT THERAPY TREATED RESECTIONS FOR OSTEOSARCOMAS
por: Syed Gardezi Saad Gardezi, et al.
Publicado: (2018)